Current Report Filing (8-k)
January 13 2021 - 8:06AM
Edgar (US Regulatory)
0000861838
false
0000861838
2021-01-13
2021-01-13
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington
D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported):
January 13, 2021
Idera Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in
Charter)
Delaware
(State
or Other Jurisdiction
of Incorporation)
|
001-31918
(Commission File
Number)
|
04-3072298
(I.R.S Employer
Identification No.)
|
505 Eagleview Blvd., Suite 212
|
|
Exton, Pennsylvania
|
19341
|
(Address of Principal Executive
Offices)
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (484) 348-1600
Check the appropriate box below if the Form 8-K filing
is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
¨
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the
Act:
Title
of each class
|
Trading
Symbol
|
Name
of each exchange on which registered
|
Common Stock, par value $0.001 per share
|
IDRA
|
Nasdaq Capital Market
|
Indicate by check mark whether the registrant is
an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or
Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 7.01
|
Regulation FD Disclosure.
|
On January 13, 2021, Idera Pharmaceuticals,
Inc. (the “Company,” “we,” “us,” and “our”) uploaded a presentation to its website,
www.iderapharma.com, discussing the state of the Company. We may rely on all or part of this presentation any time we are
discussing the current state of the Company in communications with investors or at conferences. A copy of the presentation is
attached to this Current Report on Form 8-K as Exhibit 99.1 (the “Presentation”).
The information contained in the Presentation
is summary information that is intended to be considered in the context of the Company’s Securities and Exchange Commission
(“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from time
to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although
it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other
reports or documents with the SEC, through press releases or through other public disclosure.
The information in this Current Report on
Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended
(the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated
by reference into any of the Company’s filings under the Securities Act of 1933, as amended, whether made before or after
the date hereof and regardless of any general incorporation language in such filings, except to the extent expressly set forth
by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d)
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
IDERA PHARMACEUTICALS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/ Bryant D. Lim
|
|
|
Bryant D. Lim
|
|
|
Senior V.P., General Counsel
|
|
|
|
|
|
|
Dated: January 13, 2021
|
|
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Idera Pharmaceuticals (NASDAQ:IDRA)
Historical Stock Chart
From Sep 2023 to Sep 2024